Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy
| Autor: | Kai Takaya, Tadashi Sakurai, Makoto Hikage, Yu Onodera, Kurodo Kamiya, Yohei Ozawa, Toru Nakano, Takashi Kamei, Michiaki Unno, Chiaki Sato, Takuro Konno, Yusuke Taniyama |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology Sarcopenia medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Severity of Illness Index 03 medical and health sciences 0302 clinical medicine Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Risk factor Pathological Neoadjuvant therapy Aged Psoas Muscles business.industry Gastroenterology Chemoradiotherapy Adjuvant Middle Aged Esophageal cancer musculoskeletal system medicine.disease Neoadjuvant Therapy Survival Rate body regions Cardiothoracic surgery 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female 030211 gastroenterology & hepatology Fluorouracil Cisplatin Tomography X-Ray Computed business human activities Body mass index |
| Zdroj: | Esophagus. 16:345-351 |
| ISSN: | 1612-9067 1612-9059 |
| DOI: | 10.1007/s10388-019-00670-3 |
| Popis: | The impact of sarcopenia on digestive cancer is widely known. Muscle mass, defined as the psoas muscle index (PMI), is an important parameter of sarcopenia. However, the relationship between esophageal cancer and PMI has not been fully investigated, especially in patients receiving neoadjuvant therapy. To elucidate the influence of the PMI on patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy, the progression of sarcopenia defined by the PMI, the relationship between pretherapeutic/preoperative sarcopenia and patient characteristics, and patient survival were retrospectively investigated in 82 patients with esophageal squamous cell carcinoma who underwent neoadjuvant therapy. The PMI decreased by more than 20 mm2/m2 between the pretherapeutic and preoperative periods in 75.6% of the patients. Pretherapeutic sarcopenia (low PMI) correlated with the pathological therapeutic response, postoperative recurrence, and pretherapeutic body mass index. Neoadjuvant chemoradiotherapy was associated with the progression of sarcopenia. The pretherapeutic sarcopenia group (low PMI) had worse disease-free survival (DFS) than the non-sarcopenia group. Furthermore, pretherapeutic sarcopenia (low PMI) was an independent prognostic risk factor of DFS according to univariate and multivariate analyses. The PMI may decrease during neoadjuvant therapy, especially during neoadjuvant chemoradiotherapy. Pretherapeutic sarcopenic (low PMI) patients should be followed-up more carefully postoperatively because higher risks of recurrence and poorer rates of disease-free survival are associated with these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink